Physician profile
James R Ding
NPI 1396249173
$3,356.25
in general payments reported to CMS, 2019-2025
18 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 82% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175 · 2020: $47.30 · 2021: $222 · 2022: $196 · 2023: $528 · 2024: $1,049 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,444 · Travel and Lodging: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,443.67 |
| Travel and Lodging | $271.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $927.78 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $756.63 | 2020-2025 | Dupixent |
| Aerin Medical INC. | $408.92 | 2024-2025 | |
| Optinose US, INC. | $235.63 | 2021-2025 | |
| Genzyme Corporation | $227.04 | 2023-2025 | |
| Intersect Ent, INC. | $171.05 | 2019-2020 | |
| Lilly USA, LLC | $140.79 | 2025 | Zepbound |
| Glaxosmithkline, LLC. | $121.16 | 2022-2025 | Nucala |
| Medtronic, INC. | $78.03 | 2022-2025 | Stealthstation S8 Platform, Pteye Parathyroid Detection System |
| Smith+Nephew, INC. | $59.18 | 2021-2022 | |
| Stryker Corporation | $37.76 | 2022 | |
| Boston Scientific Corporation | $34.53 | 2024 | Lithoclast |
| Integra Lifesciences Corporation | $31.84 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $30.21 | 2025 | Xhance |
| Resmed Corp | $29.47 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cochlear Americas | $25.27 | 2019 | |
| Acera Surgical, INC. | $22.77 | 2025 | Restrata Wound Matrix |
| Astrazeneca Pharmaceuticals LP | $18.19 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.